{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:17:51Z","timestamp":1770135471128,"version":"3.49.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01311","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T11:14:25Z","timestamp":1596194065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Steven N.","family":"Seyedin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret K.","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin A.","family":"Plichta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laith","family":"Abushahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny V.","family":"Arshava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpaj R.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Caster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan G.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B2","year":"","journal-title":"Esophageal and Esophagogastric Junction Cancers (Version 2.2018)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","article-title":"Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus","volume":"23","author":"Stahl","year":"2005","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/0284186X.2015.1110252","article-title":"Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer","volume":"55","author":"Shaikh","year":"2016","journal-title":"Acta Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/cncr.26586","article-title":"Failure patterns in patients with esophageal cancer treated with definitive chemoradiation","volume":"118","author":"Koshy Welsh","year":"2012","journal-title":"Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/COC.0b013e3181e841ce","article-title":"Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns","volume":"34","author":"M Greenwald","year":"2011","journal-title":"Am J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S2468-1253(17)30363-1","article-title":"Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)","volume":"3","author":"Penniment","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.2014.56.7156","article-title":"Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer","volume":"32","author":"Sudo","year":"2014","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1200\/jco.2005.23.16_suppl.4078","article-title":"A phase II study using multi-fractionation of paclitaxel and cisplatin by twice weekly schedule, plus weekly 24-hour infusion of high-dose 5-fluorouacil and leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or recurrent esophageal cancer: the final report","volume":"23","author":"Lin","year":"2005","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.3978\/j.issn.2072-1439.2014.04.16","article-title":"Current management of esophageal cancer","volume":"6","author":"D'Journo","year":"2014","journal-title":"J Thorac Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity","volume":"90","author":"Pollom","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ijrobp.2012.11.011","article-title":"Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study","volume":"85","author":"Feddock","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.adro.2017.07.011","article-title":"SBRT to adrenal metastases provides high local control with minimal toxicity","volume":"2","author":"Plichta","year":"2017","journal-title":"Adv Radiat Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/030089161109700325","article-title":"TomoTherapy stereotactic body radiation therapy (SBRT) for the salvage treatment of locally recurrent esophageal adenocarcinoma following trimodality therapy: a case report","volume":"97","author":"Russo","year":"2011","journal-title":"Tumori."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3892\/ol.2017.5605","article-title":"Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer","volume":"13","author":"Matzenauer","year":"2017","journal-title":"Oncol Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3892\/ol.2014.2087","article-title":"Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: a case report and review of the literature","volume":"8","author":"Xu","year":"2014","journal-title":"Oncol Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12539","article-title":"Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment","volume":"30","author":"Jeene","year":"2017","journal-title":"Dis Esophagus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13014-015-0358-z","article-title":"Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy","volume":"10","author":"Zhou","year":"2015","journal-title":"Radiat Oncol."},{"key":"B25","unstructured":"Efficacy and safety of biweekly docetaxel in combination with nedaplatin as second-line chemotherapy for unresectable or recurrent esophageal cancer19237\n            KanekiyoS\n            TakedaS\n            NakajimaM\n            NishiyamaM\n            KitaharaM\n            ShindouY\n          Anticancer Res.362016"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/107327481602300103","article-title":"Stereotactic body radiotherapy for recurrent unresectable head and neck cancers","volume":"23","author":"Strom","year":"2016","journal-title":"Cancer Control."},{"key":"B27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijrobp.2014.05.011","article-title":"Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity","volume":"90","author":"Stephans","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.radonc.2014.07.001","article-title":"Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors","volume":"112","author":"Wu","year":"2014","journal-title":"Radiother Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1200\/JCO.2013.51.7250","article-title":"Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies","volume":"31","author":"Sudo","year":"2013","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.21037\/acs.2017.03.02","article-title":"Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation","volume":"6","author":"Swisher","year":"2017","journal-title":"Ann Cardiothorac Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e000492","DOI":"10.1136\/jitc-2019-000492","article-title":"Abscopal responses and outcomes of anti-CTLA-4 versus anti-PD-1 immunotherapy when combined with stereotactic body radiation therapy in metastatic non-small cell lung cancer: analysis of two single-institutional prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/jco.2005.23.16_suppl.4076","article-title":"Phase II study of paclitaxel and cisplatin for metastatic or recurrent esophageal cancer","volume":"23","author":"Cho","year":"2005","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2407-12-542","article-title":"Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study","volume":"12","author":"Jingu","year":"2012","journal-title":"BMC Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.brachy.2015.02.392","article-title":"Salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients: a retrospective analysis","volume":"14","author":"Wong Hee Kam","year":"2015","journal-title":"Brachytherapy."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ijrobp.2017.06.130","article-title":"Nanotechnology-based quantification of circulating tumor cells in oligometastatic patients undergoing definitive radiation therapy","volume":"99","author":"Lindsay","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T11:14:28Z","timestamp":1596194068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":37,"alternative-id":["10.3389\/fonc.2020.01311"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01311","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"article-number":"1311"}}